Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYLTEZO vs GLYSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Rheumatoid arthritis (moderate to severe active disease),Juvenile idiopathic arthritis (polyarticular, 2 years and older),Psoriatic arthritis,Ankylosing spondylitis,Adult Crohn's disease (moderate to severe, anti-TNF naïve),Ulcerative colitis (moderate to severe in adults),Plaque psoriasis (moderate to severe chronic, adult),Hidradenitis suppurativa (moderate to severe, adult),Uveitis (non-infectious intermediate, posterior, and panuveitis in adults and pediatrics)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Adalimumab is a monoclonal antibody; it is degraded by proteolytic enzymes into small peptides and amino acids. No specific metabolic pathways or CYP450 enzymes involved.
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Adalimumab binds specifically to soluble and membrane-bound TNF-alpha; does not bind to other serum proteins; binding to specific target is high affinity but no general protein binding data reported.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Approximately 4.7–6.0 L (0.07–0.09 L/kg for a 70 kg adult); indicates distribution primarily within the vascular and interstitial spaces.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Subcutaneous: 64% (absolute bioavailability).
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment.
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No dose adjustment recommended. Not studied in patients with hepatic impairment.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
For juvenile idiopathic arthritis (2 years and older): 10-30 mg subcutaneously every other week (10 mg if <15 kg, 20 mg if 15-30 kg, 40 mg if ≥30 kg). For pediatric plaque psoriasis (4 years and older): weight-based dosing with maximum 40 mg starting dose, then 0.8 mg/kg up to 40 mg every other week. For pediatric hidradenitis suppurativa (12 years and older): 40 mg every other week.
Not recommended for pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment. Use with caution due to increased risk of infections. Monitor renal and hepatic function.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
Serious infections: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Discontinue if serious infection develops. Test for latent TB prior to initiation; treat latent TB before use. Lymphoma and other malignancies: Malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers, including adalimumab. Hepatosplenic T-cell lymphoma (HSTCL) has occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers.
None
Serious infections (including TB, invasive fungal infections, and other opportunistic infections),Malignancies (including lymphoma and HSTCL),Hepatitis B reactivation in chronic carriers,Demyelinating disease (new onset or exacerbation),Cytopenias (including pancytopenia and aplastic anemia),Congestive heart failure (worsening or new onset),Lupus-like syndrome,Serious allergic reactions (including anaphylaxis),Immunizations: Avoid live vaccines during therapy
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Severe infection (e.g., sepsis, active TB),Moderate to severe heart failure (NYHA class III/IV) - relative,Known hypersensitivity to adalimumab or any component
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
No significant food interactions reported. Avoid alcohol if liver function is compromised.
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth defects. Theoretical risk of harm to the fetus due to TNF inhibition; however, placental transfer is minimal during first trimester but increases in second and third trimester. There is evidence of increased risk of infections in neonates exposed in utero during later pregnancy. Therefore, use is not recommended in the third trimester unless clearly needed.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Adalimumab is excreted in human milk in low amounts; M/P ratio not established for adalimumab-adaz specifically. The molecular weight suggests it is unlikely to be absorbed by the infant in significant amounts. Expert consensus generally considers TNF-alpha inhibitors compatible with breastfeeding, but caution is advised. Monitor infant for potential adverse effects such as increased risk of infections or hypersensitivity.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, potentially requiring dose adjustments. However, there is insufficient evidence to recommend specific dose changes. Generally, continue same dose if benefit outweighs risk, but consider discontinuing in the third trimester to minimize fetal exposure, with dose adjustments as needed postpartum.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
CYLTEZO (adalimumab-adbm) is a TNF-alpha inhibitor biosimilar to Humira. Subcutaneous injection sites should be rotated; do not inject into tender, bruised, or scarred skin. Live vaccines are contraindicated during therapy. Screen for latent TB and hepatitis B prior to initiation. Monitor for signs of infection, especially in elderly patients. Consider temporary discontinuation if serious infection occurs. May increase risk of lymphoma and other malignancies. Not recommended in patients with moderate to severe heart failure.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Cyltezo is a biosimilar of Humira and works by reducing inflammation.,Inject the medication subcutaneously as directed; rotate injection sites.,Do not receive live vaccines (e.g., MMR, chickenpox, nasal flu) while on Cyltezo.,Contact your doctor immediately if you have signs of infection (fever, cough, painful urination).,Seek medical attention for symptoms of allergic reaction (hives, difficulty breathing, swelling).,Inform your doctor if you have a history of TB, hepatitis B, heart failure, or cancer.,Store Cyltezo in the refrigerator; do not freeze. Protect from light.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYLTEZO vs GLYSET, answered by our medical review team.
CYLTEZO is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.. GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYLTEZO and GLYSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYLTEZO is: Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.. The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYLTEZO and GLYSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYLTEZO is classified as Category C. CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth de. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.